GlaxoSmithKline Pharmaceuticals Limited

GLAXO

INE159A01016

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:18:12 2024-04-25 am EDT			5-day change	1st Jan Change
2,065 ^INR	-0.69%		+9.33%	+8.85%

03:18pm	GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology	RE
Mar. 22	GlaxoSmithKline Pharmaceuticals Limited Receives Orders from Government Authorities	CI

GlaxoSmithkline Pharmaceuticals Limited Appoints Puja Thakur as Whole-Time Director and Chief Financial Officer, Effective January 1, 2018

October 25, 2017 at 06:50 am EDT

GlaxoSmithkline Pharmaceuticals Limited appointed Ms. Puja Thakur as Whole-time Director and Chief Financial Officer, with effect from January 1, 2018. Puja has most recently bee Finance Director GSK Consumer, MEA Region based in Istanbul, Turkey.

Latest news about GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology	09:18am	RE
GlaxoSmithKline Pharmaceuticals Limited Receives Orders from Government Authorities	Mar. 22	CI
Cynata Therapeutics Names Chief Business Officer; Shares Plunge 14%	Feb. 28	MT
Glaxosmithkline Pharmaceuticals Limited Appoints Aparajita Mukherjee Rajput, Technology Lead	Feb. 28	CI
GlaxoSmithKline Pharmaceuticals Sees Sharp Decline in Fiscal Q3 Consolidated Net Profit	Feb. 13	MT
GSK India arm's Q3 profit falls on government price cap	Feb. 12	RE
GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
GlaxoSmithKline Pharmaceuticals Limited Announces Resignation of Sunder Ramachandran as Head of Commercial Excellence, Effective 12 January 2024	Dec. 29	CI
GlaxoSmithKline Pharmaceuticals Limited Announces Resignation of Abhinav Kashyap as Pharma Technology Lead	Dec. 06	CI
GSK's India unit posts Q2 profit rise on strong vaccine demand	Nov. 09	RE
GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
GlaxoSmithKline Pharmaceuticals Limited Appoints Omkar Parnandiwar as Head of Omnichannel, Effective November 1, 2023	23-10-31	CI
Glaxosmithkline Pharmaceuticals Records Rise in Fiscal Q1 Consolidated Net Profit	23-07-27	MT
India's GlaxoSmithKline Pharma posts rise in Q1 profit on steady vaccine business	23-07-26	RE
GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-26	CI
Samsung Biologics unveils $920 mln manufacturing deals for Pfizer	23-07-03	RE
A son died, his parents tried to sue. How U.S. courts protect Big Pharma	23-06-26	RE
Abbott's India arm posts 9.5% rise in fourth-quarter profit	23-05-19	RE
GlaxoSmithKline Pharmaceuticals's Net Profit Slumps in Fiscal Q4	23-05-17	MT
India's GlaxoSmithKline Pharma's pre-tax profit falls on govt pricing caps	23-05-17	RE
GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-17	CI
GlaxoSmithKline Pharmaceuticals Limited Proposes Final Dividend for the Year Ended March 31, 2023	23-05-17	CI
Pfizer's India unit posts 3% rise in Q4 profit	23-05-15	RE
Transcript : GlaxoSmithKline Pharmaceuticals Limited - Shareholder/Analyst Call	23-03-16
GlaxoSmithKline Pharmaceuticals Fiscal Q3 Consolidated Net Profit Grows	23-02-08	MT

Chart GlaxoSmithKline Pharmaceuticals Limited

Duration

Period

Chart GlaxoSmithKline Pharmaceuticals Limited

More charts

Company Profile

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. It has three product areas: vaccines, specialty and general medicines. Its general medicines business has a portfolio of medicines in anti-infectives, pain, dermatology and vitamins. Its general medicines brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact and Physiogel. Its T-bact brand products are used in specific types of bacterial skin infections. The Company's vaccine brands include Shingrix, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicines business is focused on developing medicines for respiratory diseases and human immunodeficiency virus. The Company is also building its presence in other therapeutic areas, such as immunology and oncology. Its specialty medicines brands include Nucala and Trelegy Ellipta.

Sector

Pharmaceuticals

Calendar

2024-05-16 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for GlaxoSmithKline Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2,080 INR

Average target price

2,141 INR

Spread / Average Target

+2.95%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GLAXOSMITHKLINE PHARMACEUTICALS LIMITED	+8.85%	4.23B
NOVO NORDISK A/S	+24.08%	562B
JOHNSON & JOHNSON	-6.42%	358B
MERCK & CO., INC.	+18.66%	322B
ABBVIE INC.	+7.42%	297B
ASTRAZENECA PLC	+12.89%	219B
NOVARTIS AG	+5.81%	199B
ROCHE HOLDING AG	-10.35%	196B
PFIZER, INC.	-10.81%	149B
AMGEN INC.	-6.71%	146B

Other Pharmaceuticals